Entinostat Plus Chemotherapy as Second Treatment for Advanced Bladder Cancer
Tests entinostat with chemotherapy in adults whose advanced bladder cancer needs a second treatment.
Plain-language title generated from the registry record
Registry title: Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer
Key facts
- Where
- Nanjing, ChinaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07261592, who can take part
Where in China
- Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing UniversityNanjing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Trial code
- NCT07261592
- Record updated
- 3 December 2025
- Original description
This single-center single-arm, open-label prospective clinical trial aimed to evaluate the efficacy and safety of entinostat combined with chemotherapy as second-line therapy for unresectable locally advanced or metastatic bladder cancer.Read full original descriptionShow less
Entinostat Combined With Chemotherapy as Second-line Therapy for Unresectable Locally Advanced or Metastatic Bladder Cancer: A Single-arm, Prospective Clinical Trial
This single-center single-arm, open-label prospective clinical trial aimed to evaluate the efficacy and safety of entinostat combined with chemotherapy as second-line therapy for unresectable locally advanced or metastatic bladder cancer.
Inclusion: Histopathologic confirmed unresectable advanced or metastatic bladder cancer, except for those with squamous differentiation, glandular differentiation or both; Failure of first-line treatment; There is at least one measurable lesion according to RECIST 1.1; Archived tumor tissue samples or tumor biopsies must be provided; ECOG score of 0-1 an an estimated survival of at least 6 months; Adequate organ function; Patients voluntarily participated in this study, signed the informed consent form, and had good compliance; Women with fertility must consent to contraception during the study and for 6 months after the last dose of study drug.
Exclusion: Patients who received platinum-based chemotherapy after failure of first-line treatment; Patients who received platinum-based chemotherapy withnin a 24 month before this trial; Those who have received other anti-tumor treatment or participated in other clinical studies within 4 weeks before the start of the study, or have not recovered from the last toxicity (except grade 2 hair loss and grade 1 neurotoxicity); Concomitant disease such as uncontrolled hypertension or diabetes, renal inadequacy, myocardial infarction, severe angina; Patients with serious physical or mental illnesses; Female subjects who are pregnant, breastfeeding or planning to become pregnant during the study.